Pfenex (PFNX) Misses Q1 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. HUM
8. NVDA
9. CSCO
10. KTOS

Go back to Pfenex (PFNX) Misses Q1 EPS by 5c

Pfenex Reports First Quarter 2015 Results and Provides Business Update

May 14, 2015 8:02 AM EDT

SAN DIEGO, May 14, 2015 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today reported financial results for the first quarter ended March 31, 2015 and provided a business update.

"The first quarter 2015 was very active for Pfenex, with our announcement in February of the collaboration with Hospira for our lead compound, PF582, a biosimilar candidate to Lucentis.  As we have previously disclosed,... More